Please assess the completion status of the following clinical trial:

Trial Title: Oral Anticoagulation in Haemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥ 18 years)~* Patient on hemodialysis treatment for at least 1 month~* Patient with a history of, or presenting a new episode of atrial fibrillation (either permanent or paroxysmal).~* Patient with a CHADS2VASC score ≥2~* Patient with high risk of bleeding as defined by (1) HASBLED score ≥3 OR (2) HASBLED ≥ CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c), particularly cerebral or gastrointestinal, OR (4) prior recurrent (\>2) history of falls.~* Patient capable of understanding information about the study and of giving his/her consent~* Patient informed of the preliminary medical exam results~* Patient with healthcare insurance~* Written consent signed~Exclusion Criteria:~* Formal indication to oral anticoagulation beside atrial fibrillation (mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome)~* Life expectancy \< 6 months (e.g., terminal cancer)~* Live donor transplantation scheduled within 6 months~* Pregnancy (β-HCG blood-based assay)or nursing (lactating) women~* Women of child bearing potential, unless they are using an effective method of birth control~* Patient under legal guardianship~* Patients under law protection~* Known hypersensibility to coumadin or indoine derivatives or to any excipients (CI to oral AVK)~* Severe liver failure (CI to oral AVK)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No anticoagulation (Type: EXPERIMENTAL): No oral anticoagulation, and no monitoring of the INR.
- Oral anticoagulation with vitamin K antagonists (Type: ACTIVE_COMPARATOR): VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.~Antiplatelet therapy will be provided only if recent acute coronary syndrome (\< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population.

Based on this trial design, predict the completion outcome and termination type (if applicable).